15183-37-6 Usage
Description
Estetrol, also known as E4, is an estrogen steroid hormone that is exclusively produced by the fetal liver from estradiol and estriol during pregnancy. It is characterized by its off-white solid appearance and has a unique binding affinity to estrogen receptors (ERs), with a 4-fold higher affinity for ERα over ERβ. Estetrol exhibits estrogenic effects in most tissues expressing ERs, such as bone, brain, vagina, and endometrium. Interestingly, in breast tumors, estetrol acts as an estrogen antagonist in the presence of estradiol, preventing tumor growth.
Uses
Used in Pharmaceutical Industry:
Estetrol is used as a hormone for various applications, including the treatment of menopausal symptoms, osteoporosis, and vaginal atrophy. Its unique binding affinity to estrogen receptors allows for targeted effects in specific tissues, reducing the risk of side effects associated with traditional hormone replacement therapies.
Used in Oncology:
Estetrol is used as an estrogen antagonist in the treatment of breast tumors. In the presence of estradiol, it prevents tumor growth by blocking the estrogen receptors, thus inhibiting the proliferation of cancer cells.
Used in Obstetrics and Gynecology:
Estetrol is used as a hormone during pregnancy, as it is synthesized exclusively by the fetal liver and reaches the maternal circulation through the placenta. Its presence during pregnancy plays a crucial role in the development of the fetus and the maintenance of a healthy pregnancy.
Used in Drug Development:
Estetrol's unique properties make it a promising candidate for the development of new drugs targeting various conditions related to estrogen receptor imbalance, such as hormone-related disorders and certain types of cancer. Researchers are exploring its potential in the creation of novel therapeutic agents with fewer side effects and improved efficacy.
Check Digit Verification of cas no
The CAS Registry Mumber 15183-37-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,5,1,8 and 3 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 15183-37:
(7*1)+(6*5)+(5*1)+(4*8)+(3*3)+(2*3)+(1*7)=96
96 % 10 = 6
So 15183-37-6 is a valid CAS Registry Number.
InChI:InChI=1/C18H24O4/c1-18-7-6-12-11-5-3-10(19)8-9(11)2-4-13(12)14(18)15(20)16(21)17(18)22/h3,5,8,12-17,19-22H,2,4,6-7H2,1H3/t12?,13-,14?,15?,16?,17+,18+/m1/s1
15183-37-6Relevant articles and documents
Synthesis of 15α-hydroxyestrogen 15-N-acetylglucosaminides
Suzuki, Emako,Namba, Susumu,Kurihara, Hiroyuki,Goto, Junichi,Matsuki, Yasuhiko,Nambara, Toshio
, p. 277 - 284 (1995)
The synthesis of 15-N-acetylglucosaminides of 15α-hydroxyestrone, 15α-hydroxyestradiol, and 15α-hydroxyestriol (estetrol) is described.The latter two were prepared by condensation of 2-acetamido-1α-chloro-1,2-dideoxy-3,4,6-tri-O-acetyl-D-glucopyranose with appropriately protected 15α-hydroxyestrogens by the Koenigs-Knorr reaction employing cadmium carbonate as a catalyst.Subsequent removal of protecting groups with methanolic potassium hydroxide provided the desired conjugates. 15α-Hydroxyestrone 15-N-acetylglucosaminide was synthesized from the corresponding 15α-hydroxyestradiol derivative by Jones oxidation followed by brief alkaline hydrolysis.These conjugates underwent enzymatic hydrolysis with β-N-acetylglucosaminidase from Jack beans to produce 15α-hydroxyestrogens. - Keywords: 15α-hydroxyestrogen; N-acetylglucosaminide; Koenigs-Knorr reaction; 15-methoxyestrogen; β-N-acetylglucosaminidase
PROCESS FOR PREPARING (15ΑLPHA,16ΑLPHA,17ΒETA)-ESTRA-1,3,5(10)-TRIENE-3,15,16,17-TETROL (ESTETROL) AND INTERMEDIATES OF SAID PROCESS
-
Page/Page column 14-15, (2021/04/02)
The present invention relates to a process for preparing (15α,16α,17β)-Estra-1,3,5(10)-triene-3,15,16,17-tetrol, also known as Estetrol, having the formula shown below: (I)
Process for the preparation of estetrol
-
, (2011/11/12)
The present invention relates to a process for the preparation of estra-1,3,5(10)-trien-3,15α,16α,17β-tetraol (estetrol), via a silyl enol ether derivative 17-B-oxy-3-A-oxy-estra-1,3,5(10),16-tetraene, wherein A is a protecting group and B is ―Si(R2)3. The invention further relates to a process for the synthesis of 3-A-oxy-estra-1,3,5(10),15-tetraen-17-one, wherein A is a protecting group, via said silyl enol ether derivative.